您的位置: 首页 > 农业专利 > 详情页

Use of laquinimod in high doses for the treatment of Multiple sclerosis
专利权人:
LTD.;TEVA PHARMACEUTICAL INDUSTRIES
发明人:
DAN BAR-ZOHAR
申请号:
ARP130101459
公开号:
AR090885A1
申请日:
2013.04.29
申请国别(地区):
AR
年份:
2014
代理人:
摘要:
Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome, Methods for treating a Human subject by providing neuroprotection to the Human subject.And Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated syndrome by increasing the time to progression of disease is confirmed, the increased time to Relapse or confirmed the reduction in brain atrophy Human patient,Which comprises administering to the Human Patient or subject orally Daily doses of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof.This also provides an oral pharmaceutical dosage Unit of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof and a pharmaceutically acceptable vehicle for use in the treatment of a Human Patient affected by multiple sclerosis or P Introduced a clinically isolated Syndrome,For use in the treatment of a Human subject by providing neuroprotection to the Human subject, or for use in the treatment of a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome through the increased time to progression Disease was confirmed,The increased time to Relapse or confirmed the reduction of Brain atrophy in the Human patient.Métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado, métodos para tratar a un sujeto humano mediante la provisión de neuroprotección al sujeto humano, y métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado mediante el incremento del tiempo hasta progresión de enfermedad confirmada, el incremento del tiempo hasta recaída confirmada o la reducción de atrofia cerebral en el paciente humano, que comprende administrar oralmente al paciente humano o sujeto una dosis diaria de aproximadamente 1,2 mg de laquinimod o una sal del mismo farmacéuticamente aceptable.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充